CIK 0001636282
- Large accelerated filer
Spyre Therapeutics, Inc.
Sign in to watch- Ticker
- SYRE
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- EIN
- 464312787
- Phone
- +1 617-651-5940
- Business address
- 221 CRESCENT STREET, BUILDING 23, SUITE 105, WALTHAM, MA, 02453
- Former names
- Aeglea BioTherapeutics, Inc.
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $12,349,597
- in 6 filings, $12.3M under 10b5-1 plans
Net −$12,349,597. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 21 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2020-02-14 | Sloan Leslie Chief Operating Officer | Grant or award · Employee Stock Option (right to buy) | +100,000 | 100,000 | ||
| 2020-02-14 | Rao Madduri Ravin Chief Medical Officer | Grant or award · Employee Stock Option (right to buy) | +25,000 | 25,000 | ||
| 2020-02-14 | Quinn Anthony G. President & CEO | Grant or award · Employee Stock Option (right to buy) | +301,000 | 301,000 | ||
| 2020-02-14 | Hanley Jr. Michael Conick Chief Commercial Officer | Grant or award · Employee Stock Option (right to buy) | +25,000 | 25,000 | ||
| 2019-11-01 | Rao Madduri Ravin Chief Medical Officer | Grant or award · Employee Stock Option (right to buy) | +130,000 | 130,000 | ||
| 2019-10-21 | Hanley Jr. Michael Conick Chief Commercial Officer | Grant or award · Employee Stock Option (right to buy) | +130,000 | 130,000 | ||
| 2019-10-04 | Quinn Anthony G. President & CEO | Option exercise | +662 | $5.46 | $4K | 354,305 |
| 2019-10-04 | Quinn Anthony G. President & CEO | Option exercise | +17,603 | $6.31 | $111K | 371,908 |
| 2019-10-04 | Quinn Anthony G. President & CEO | Option exercise · Stock Option (right to buy) | −662 | 0 | ||
| 2019-10-04 | Quinn Anthony G. President & CEO | Option exercise · Stock Option (right to buy) | −17,603 | 119,914 | ||
| 2019-06-14 | Quinn Anthony G. President & CEO | Purchase | +5,282 | $6.23 | $33K | 353,643 |
| 2019-06-13 | Quinn Anthony G. President & CEO | Purchase | +14,406 | $6.17 | $89K | 348,361 |
| 2019-06-12 | Quinn Anthony G. President & CEO | Purchase | +12,217 | $6.11 | $75K | 333,955 |
| 2019-06-07 | LAWLIS V BRYAN Director | Grant or award · Director Stock Option (right to buy) | +12,400 | 12,400 | ||
| 2019-06-07 | Shanafelt Armen Director | Grant or award · Director Stock Option (right to buy) | +12,400 | 12,400 | ||
| 2019-06-07 | Mahatme Sandesh Director | Grant or award · Director Stock Option (right to buy) | +12,400 | 12,400 | ||
| 2019-06-07 | Magovcevic Ivana Director | Grant or award · Director Stock Option (right to buy) | +12,400 | 12,400 | ||
| 2019-06-07 | Cox Russell J. Director | Grant or award · Director Stock Option (right to buy) | +12,400 | 12,400 | ||
| 2019-06-07 | Bruhn Suzanne Louise Director | Grant or award · Director Stock Option (right to buy) | +12,400 | 12,400 | ||
| 2019-05-22 | Quinn Anthony G. President & CEO | Purchase | +3,809 | $6.86 | $26K | 321,738 |
Page 14 of 19 · 372 trades